NEW YORK – Liquid biopsy firm Biocept said Monday that Blue Cross Blue Shield affiliate Highmark has made a positive coverage determination for Biocept’s Target Selector liquid biopsy test in the diagnosis and treatment of patients with non-small cell lung cancer.